Metastatic pancreatic cancer is an aggressive form of cancer that spreads from the pancreas to other parts of the body. According to Xiao Li et al., 2025, in 2021, there were 508,532 new cases of pancreatic cancer globally, with 273,617 or 53.8% occurring in males. Current therapies include chemotherapy, targeted therapies, and immunotherapy, though prognosis remains poor. According to the metastatic pancreatic cancer pipeline analysis by Expert Market Research, there is a growing focus on novel molecular therapies, combination regimens, and improved drug delivery systems. With increasing incidence and ongoing R&D, the pipeline is expected to expand significantly in the coming years.
Major companies involved in the metastatic pancreatic cancer pipeline analysis include Erasca, Inc., Lantern Pharma Inc., and others.
Leading drugs currently in the pipeline include LP-184, TST001, OATD-02, and others.
The pipeline shows significant expansion driven by novel targeted therapies, immunotherapies, and combination regimens. Increasing clinical trial activity and breakthrough designations indicate accelerated development and potential market entry in the coming years.
The Metastatic Pancreatic Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into metastatic pancreatic cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic pancreatic cancer. The metastatic pancreatic cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic pancreatic cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with metastatic pancreatic cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to metastatic pancreatic cancer.
Read more about this report - Request a Free Sample
Metastatic pancreatic cancer is an aggressive form of cancer that occurs when malignant cells from the pancreas spread to other organs, commonly the liver or lungs. It develops due to genetic mutations and abnormal cell division, often remaining asymptomatic until advanced stages. Risk factors include chronic pancreatitis, smoking, obesity, and family history.
Metastatic pancreatic cancer treatments include chemotherapy, targeted therapy, and immunotherapy to slow disease progression, improve survival, and manage symptoms, with combinations tailored based on patient health and tumor genetics. In February 2024, the FDA approved the four-drug combination Nalirifox, comprising irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, for first-line therapy, based on the phase 3 NAPOLI 3 trial led by Dr. Zev Wainberg. This regimen demonstrated superior overall survival compared to prior two-drug protocols, marking a significant advancement in frontline treatment.
According to Xiao Li et al., 2025, there were 508,532 incident cases of pancreatic cancer globally in 2021, with 53.8% in males. Age-standardized incidence rates slightly decreased from 6.0 per 100,000 in 2019 to 5.9 per 100,000 in 2021. Deaths increased by 3.9% to 505,752, and disability-adjusted life years rose by 3.5% to 11.3 million. In the United States, the American Cancer Society estimates 67,440 new cases and 51,980 deaths in 2025. The rising burden underscores the urgent need for effective therapeutic interventions.
This section of the report covers the analysis of metastatic pancreatic cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The metastatic pancreatic cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 50%, covers a major share of the total metastatic pancreatic cancer clinical trials. It is followed by phase I at 42%. Phase III contributes 5%. The strong presence of early and mid-phase drugs indicates a robust pipeline, which can drive innovation, expand treatment options, and positively impact market growth.
The drug molecule categories covered under the metastatic pancreatic cancer pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The metastatic pancreatic cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic pancreatic cancer. Cytotoxic chemotherapy remains a key approach in the metastatic pancreatic cancer drug pipeline. For instance, in February 2024, Ipsen’s Onivyde® (irinotecan liposome injection) combined with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) was approved as a first-line therapy. It works by inhibiting topoisomerase I, preventing cancer cell replication and promoting tumor cell death, thereby improving overall survival and progression-free survival in patients.
The EMR report for the metastatic pancreatic cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed metastatic pancreatic cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in metastatic pancreatic cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for metastatic pancreatic cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of metastatic pancreatic cancer drug candidates.
LP-184, sponsored by Lantern Pharma Inc., is a synthetically lethal small molecule designed to induce DNA double-strand breaks in cancer cells via bioactivation by prostaglandin reductase 1 (PTGR1). This Phase 1/2 study is evaluating the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) in patients with advanced or metastatic solid tumors, including metastatic pancreatic cancer. The study is examining pharmacokinetics, clinical activity, and potential efficacy in DDR gene-altered tumors, with LP-184 administered on Day 1 and Day 8 of each 21-day cycle.
TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody being developed by Suzhou Transcenta Therapeutics Co., Ltd. This Phase I/IIa trial is examining its safety, tolerability, and pharmacokinetics as monotherapy or in combination with nivolumab or standard chemotherapy in patients with advanced or metastatic solid tumors, including pancreatic cancer. TST001 leverages enhanced antibody-dependent cellular cytotoxicity to target CLDN18.2-expressing tumor cells and is demonstrating promising anti-tumor activity.
OATD-02 is being developed by Molecure S.A. as a first-in-class, dual-acting arginase inhibitor targeting both tumor immunity and metabolism. This Phase I study is evaluating the safety, tolerability, and antineoplastic activity of oral OATD-02 in patients with advanced or metastatic solid tumors, including pancreatic cancer. The study is examining whether OATD-02 can enhance tumor responses by increasing arginine levels or exert intrinsic anti-tumor effects. Enrollment includes up to 40 patients, and treatment is continuing for up to six months.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Metastatic Pancreatic Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic pancreatic cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into metastatic pancreatic cancer collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share